Mitsubishi UFJ Trust & Banking Corp Has $170.91 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Mitsubishi UFJ Trust & Banking Corp has reduced its stake in Gilead Sciences by 5.6% during the first quarter, now holding 1,525,267 shares valued at approximately $170.9 million.
• Several large investors have significantly changed their positions in Gilead, with notable increases from Brighton Jones LLC (20.6%) and OneAscent Financial Services LLC (45.1%) during the previous quarter.
• Wall Street analysts are bullish on Gilead, with recent upgrades and an average target price of $112.36, indicating a consensus rating of "Moderate Buy".

Mitsubishi UFJ Trust & Banking Corp lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,525,267 shares of the biopharmaceutical company's stock after selling 90,636 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.12% of Gilead Sciences worth $170,906,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Redwood Financial Network Corp lifted its stake in shares of Gilead Sciences by 4.0% during the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock valued at $234,000 after acquiring an additional 98 shares during the period. Argentarii LLC increased its holdings in Gilead Sciences by 3.0% in the first quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 99 shares during the last quarter. Nicolet Advisory Services LLC increased its holdings in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company's stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Peak Financial Advisors LLC increased its holdings in Gilead Sciences by 1.7% in the first quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after purchasing an additional 100 shares during the last quarter. Finally, Perkins Coie Trust Co increased its holdings in Gilead Sciences by 2.6% in the first quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock valued at $435,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the transaction, the chief financial officer owned 162,610 shares in the company, valued at $18,054,588.30. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $8,984,175 in the last quarter. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $1.33 during trading hours on Monday, reaching $114.51. 5,633,402 shares of the stock were exchanged, compared to its average volume of 5,536,027. The stock's fifty day simple moving average is $110.51 and its 200 day simple moving average is $106.91. Gilead Sciences, Inc. has a 52 week low of $72.43 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm has a market capitalization of $142.44 billion, a price-to-earnings ratio of 24.11, a P/E/G ratio of 0.71 and a beta of 0.33.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Oppenheimer lowered their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Eight analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $112.36.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.